Compare Riot Platforms Inc (RIOT) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Riot Platforms Inc vs Sanofi SA — how do they compare? Riot Platforms Inc trades at $21.83 (market cap $8.29B), while Sanofi SA trades at $43.12 (market cap $103.41B). The key difference: Sanofi SA is far larger — about 12.5× Riot Platforms Inc's market cap, and Sanofi SA pays a 5.65% dividend while Riot Platforms Inc pays none. Which is the better fit depends on your goals.
| RIOT | SNY | |
|---|---|---|
Market Cap | $8.29B | $103.41B |
Sector | Technology | Health |
52-Week High | $28.67 | $52.34 |
52-Week Low | $11.83 | $41.33 |
Enterprise Value | $8.69B | $123.44B |
Dividend Yield | — | 5.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Riot Platforms (RIOT) trades at $22.26, up 2.11% with a bullish technical signal. The stock shows strong analyst support with 94.7% buy ratings and a $33.00 consensus price target, representing 48% upside potential. Recent news highlights a transformative $9.1 billion, 20-year AI data center deal with Anthropic, shifting the company's focus from Bitcoin mining to high-margin AI infrastructure. However, fundamental challenges persist with negative net income margins and consecutive earnings misses.
The outlook balances transformative AI opportunities against current financial weakness. The Anthropic partnership provides long-term revenue visibility but execution risks remain high. With negative profitability and cash flow challenges, investors must weigh the company's AI transition potential against its current financial instability in a volatile market environment.
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
